Rationale for the GEMSTONE-302 Study in Lung Cancer
Jamie E. Chaft, MD, discusses the background behind the phase 3 GEMSTONE-302 trial of platinum-based chemotherapy with placebo or CS1001 as front-line treatment for patients with advanced non-small cell lung cancer.
Jamie E. Chaft, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the background behind the phase 3 GEMSTONE-302 trial of platinum-based chemotherapy with placebo or CS1001 as front-line treatment for patients with advanced non-small cell lung cancer (NSCLC).
Multiple studies have shown that the combination of chemotherapy and immunotherapy is better than chemotherapy and placebo, says Chaft. Research has also shown that chemotherapy plus immunotherapy is comparable to immunotherapy alone in patients with tumors that highly expressed PD-L1.
The GEMSTONE-302 is another example of these prior studies but focuses on patients in China. Chaft explains that positive results would not be surprising to see and there is hope that the treatment strategy will allow an additional therapeutic option for patients with advanced NSCLC.
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC
April 7th 2024An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
April 5th 2024During a Case-Based Roundtable® event, Christine Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non-small cell lung cancer in the first article of a 2-part series.
Read More
